Oppenheimer analyst Brian Nagel maintained a Buy rating on Chromadex (CDXC) today and set a price target of $6.00. The company’s shares closed last Monday at $4.16.
According to TipRanks.com, Nagel is a 5-star analyst with an average return of 10.4% and a 65.8% success rate. Nagel covers the Consumer Goods sector, focusing on stocks such as Dick’s Sporting Goods, Lululemon Athletica, and The Lovesac Company.
Chromadex has an analyst consensus of Strong Buy, with a price target consensus of $6.33, representing a 63.1% upside. In a report issued on April 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.95 and a one-year low of $2.50. Currently, Chromadex has an average volume of 342.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
